 |
PDL BioPharma to Hold Annual Meeting of Stockholders on June 22, 2011
Apr 18, 2011
|
5.6 KB |
|
| |
INCLINE VILLAGE, Nev., April 18, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Wednesday, June 22, 2011 at 10:00 a.m. Pacific Time for all stockholders of record on ...
|
|
PDL BioPharma Announces Conversion Rate Adjustments for 2.00% Convertible Senior Notes Due February 15, 2012 and 2.875% Convertible Senior Notes Due February 15, 2015
Mar 8, 2011
|
6.6 KB |
|
| |
INCLINE VILLAGE, Nev., March 8, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced an adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes) and its 2.875% Convertible Senior Notes due February...
|
|
PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million
Mar 7, 2011
|
10.6 KB |
|
| |
INCLINE VILLAGE, Nev., March 7, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the first quarter ending March 31, 2011 of approximately $83 million, as compared with actual results of $62 ...
|
|
PDL BioPharma Announces Regular Quarterly Dividend Policy
Feb 28, 2011
|
7.0 KB |
|
| |
INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that its board of directors has adopted a regular dividend policy for 2011 and beyond and declared that the four quarterly dividends to be paid to its stockholders in 2011 will be $0.15 per ...
|
|
PDL BioPharma Announces European Patent Office Determination of Validity of PDL's European Patent is Final
Feb 28, 2011
|
6.5 KB |
|
| |
INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that the Technical Board of Appeal of the European Patent Office (EPO) has cancelled its hearing in which three appellants sought to have a 2007 decision upholding PDL's European Patent No. 0 451 216B (the '216B Patent) ...
|
|
PDL Settles Litigation and Resolves Other Disputes
Feb 28, 2011
|
6.7 KB |
|
| |
INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has entered into a definitive settlement agreement with Novartis that resolves all disputes between them. Under the settlement agreement, PDL agreed to dismiss its claims against Novartis in its action in ...
|
|
PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results
Feb 28, 2011
|
28.4 KB |
|
| |
INCLINE VILLAGE, Nev., Feb. 28, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2010.
Total revenues in 2010 were $345.0 million, compared to ...
|
|
PDL BioPharma to Present at Upcoming Conferences
Feb 24, 2011
|
6.3 KB |
|
| |
INCLINE VILLAGE, Nev., Feb. 24, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the following upcoming conferences:
...
|
|
PDL BioPharma to Announce Fourth Quarter and Year End 2010 Financial Results on February 28, 2011
Feb 22, 2011
|
6.5 KB |
|
| |
INCLINE VILLAGE, Nev., Feb. 22, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the Company will release its fourth quarter and full year financial results for the period ended December 31, 2010 on Monday, February 28, 2011 afte...
|
|
MedImmune and PDL BioPharma Resolve Patent Disputes
Feb 16, 2011
|
6.7 KB |
|
| |
GAITHERSBERG, Md. and INCLINE VILLAGE, Nev., Feb. 16, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (Nasdaq: PDLI) (PDL) today announced that PDL and MedImmune, LLC have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to MedImmune's product Synagis...
|
|
UCB and PDL BioPharma Resolve Patent Disputes
Feb 8, 2011
|
8.5 KB |
|
| |
BRUSSELS and INCLINE VILLAGE, Nev., Feb. 8, 2011 /PRNewswire via COMTEX/ --UCB SA (Euronext Brussels: UCB), on behalf of its affiliate UCB Pharma S.A. (UCB), and PDL BioPharma, Inc. (Nasdaq: PDLI) (PDL) today jointly announced that the companies have entered into a definitive settlement agreement that resolves all legal disputes between t...
|
|
PDL BioPharma Appoints Caroline Krumel as Vice President of Finance and Thanks Karen Wilson for her Contributions
Jan 25, 2011
|
7.1 KB |
|
| |
INCLINE VILLAGE, Nev., Jan. 25, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced the appointment of Caroline Krumel, CPA to the position of vice president of finance and chief accounting officer, effective January 31, 2011. Ms. Krumel will ...
|
|
PDL BioPharma Announces Decisions on Summary Judgment in its Litigation with MedImmune
Jan 10, 2011
|
9.4 KB |
|
| |
INCLINE VILLAGE, Nev., Jan. 10, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that on January 7, 2011, the United States District Court for the Northern District of California issued summary judgment order deciding certain issues favor...
|
|
PDL BioPharma to Present at the 29th Annual JP Morgan Healthcare Conference
Jan 5, 2011
|
6.1 KB |
|
| |
INCLINE VILLAGE, Nev., Jan. 5, 2011 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 29th Annual JP Morgan Healthcare Conference in S...
|
|
U.S. Patent and Trademark Office Terminates Interference Proceeding in Favor of PDL BioPharma, Inc.
Dec 20, 2010
|
5.6 KB |
|
| |
INCLINE VILLAGE, Nev., Dec. 20, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that on December 15, 2010, the U.S. Patent and Trademark Office (the PTO) terminated its interference proceeding between certain claims of the Company's Queen et al., U.S. Patent No. 5,585,0...
|
|
PDL BioPharma Provides Fourth Quarter 2010 Revenue Guidance of $74 Million
Dec 1, 2010
|
10.0 KB |
|
| |
INCLINE VILLAGE, Nev., Dec. 1, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2010 of approximately $74 million, as compared with actual results of $58.3 million for the fourth quarter of 2009, a 27 percent year-over-year increase. The gro...
|
|
PDL BioPharma Announces Third Quarter 2010 Financial Results
Nov 10, 2010
|
23.1 KB |
|
| |
INCLINE VILLAGE, Nev., Nov. 10, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the third quarter and nine months ended September 30, 2010.
Financial Results for the Third Quarter Ended September 30, 2010
Revenues for the third quarter of 2010 wer...
|
|
PDL BioPharma Completes Exchange to Retire $92.0 Million of 2.00% Convertible Notes Due August 2012
Nov 5, 2010
|
5.8 KB |
|
| |
INCLINE VILLAGE, Nev., Nov. 5, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that it has completed the exchange of $92.0 million in aggregate principal of the Company's outstanding 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes) in separate, privately negotiated exchange tran...
|
|
PDL BioPharma to Announce Third Quarter 2010 Financial Results on November 10, 2010
Nov 2, 2010
|
6.3 KB |
|
| |
INCLINE VILLAGE, Nev., Nov. 2, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the Company will release its third quarter financial results on Wednesday, November 10, 2010 after the markets close. PDL's management will host a conference call and webcast at 4:30 p.m. Eastern Time to discu...
|
|
PDL BioPharma to Present at Oppenheimer and Lazard Capital Markets Annual Healthcare Conferences
Oct 28, 2010
|
6.2 KB |
|
| |
INCLINE VILLAGE, Nev., Oct 28, 2010 /PRNewswire via COMTEX/ --PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that management is scheduled to present at the following upcoming investor conferences.
...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter